AI assistant
Sending…
Q32 Bio Inc. — Director's Dealing 2020
Jan 30, 2020
34891_dirs_2020-01-29_68366390-77c1-46eb-8ab8-113d29d99815.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2019-11-18
Reporting Person: Gregory Richard J. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-11-18 | COMMON STOCK | M | 10806 | $0.03 | Acquired | 10806 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-11-18 | Employee Stock Option | $0.03 | M | 10806 | Disposed | 2025-05-28 | Common Stock (10806) | Direct |
Footnotes
F1: This option is fully vested.
More from Q32 Bio Inc.
Regulatory Filings
2026
May 27
Interim / Quarterly Report
2026
May 5
Regulatory Filings
2026
May 5
Annual Report
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 30
Regulatory Filings
2026
Apr 24
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Feb 27